Anavex Life Sciences (AVXL) Cash from Financing Activities (2010 - 2025)

Anavex Life Sciences (AVXL) has 16 years of Cash from Financing Activities data on file, last reported at $36.3 million in Q4 2025.

• For the quarter ending Q4 2025, Cash from Financing Activities rose 5030.37% year-over-year to $36.3 million; the trailing twelve-month figure through Dec 2025 stood at $45.0 million (up 256.85% YoY), and the FY2025 full-year result was $9.4 million, down 21.22% from the prior year.
• Cash from Financing Activities grew to $36.3 million in Q4 2025, from $10.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $89.2 million in Q2 2021 to a low of -$2.1 million in Q2 2025.
• A 5-year average of $11.8 million and a median of $3.5 million in 2021 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities jumped 83341.56% in 2023 and slumped 147.1% in 2025, its largest moves.
• Tracing AVXL's Cash from Financing Activities over 5 years: stood at $2.5 million in 2021, then tumbled by 89.84% to $258000.0 in 2022, then slumped by 77.13% to $59000.0 in 2023, then soared by 1100.0% to $708000.0 in 2024, then surged by 5030.37% to $36.3 million in 2025.
• Business Quant data shows AVXL's Cash from Financing Activities at $36.3 million in Q4 2025, $10.0 million in Q3 2025, and -$2.1 million in Q2 2025.